University of Strathclyde

Kowa Company Limited

The University of Edinburgh

Alan Lang Harvey

Mototsugu Kabeya

Toru Kanke

Junichi Kawagoe

Pu Wang

Robin Plevin

Kevin Thomas Shaw

Maureen Theresa McKenna

George Rennet Proctor

Lu Jiang

Steven John Mullins

Robert Ramage

Louise Claire Young

The present invention relates to a peptide derivative represented by the general formula (I) or a salt thereof: Z-(CH)&#x2014;CO&#x2014;NH-Leu-Ile-Gly-AA-AA-CO&#x2014;R (I) wherein Z represents an aryl group which may or may not have a substituent or a heteroaryl group which may or may not have a substituent; n represents 0, 1 or 2: AA-AArepresents Lys-Val or Arg-Leu; and R represents &#x2014;OH or &#x2014;NH, and relates to a pharmaceutical composition comprising a peptide derivative represented by the general formula (I) or a salt thereof, and a pharmaceutically acceptable carrier thereof. The peptide derivative is useful as a prophylactic and therapeutic agent of dysfunction of masticatory, dysphagia, dysgeusia, ozostomia, intra-oral cavity dysphoria, intra-oral cavity infections, intra-oral cavity inflammations, dry eye, ectocornea detachment, keratitis, corneal ulcer, conjunctivitis, stomach ulcer, duodenal ulcer, gastritis, diarrhea, enteritis or Sjogren's syndrome.

Par-2-activating peptide derivative and pharmaceutical composition using the same

Polycyclic compounds

Growing community of inventors

Strathclyde, United Kingdom

Alan Lang Harvey